Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €232.10 EUR
Change Today +1.00 / 0.43%
Volume 4.2K
As of 11:35 AM 04/30/15 All times are local (Market data is delayed by at least 15 minutes).

virbac sa (VIRP) Snapshot

Open
€230.50
Previous Close
€231.10
Day High
€232.45
Day Low
€227.00
52 Week High
03/6/15 - €257.95
52 Week Low
08/12/14 - €139.90
Market Cap
2.0B
Average Volume 10 Days
6.8K
EPS TTM
€7.52
Shares Outstanding
8.5M
EX-Date
06/20/14
P/E TM
30.9x
Dividend
--
Dividend Yield
0.82%
Current Stock Chart for VIRBAC SA (VIRP)

Related News

No related news articles were found.

virbac sa (VIRP) Related Businessweek News

No Related Businessweek News Found

virbac sa (VIRP) Details

Virbac SA develops, manufactures, and sells vaccines and medicines to prevent and treat pathologies for companion and food-producing animals in France, the rest of Europe, North America, Latin America, Africa, the Middle East, Asia, and the Pacific region. The company’s products comprise Agrimin, a food supplement for cattle; Anxitane, a food supplement prescribed for dogs and cats; CaniLeish, a vaccine against canine leishmaniosis; Carprox, tablets for dogs to reduce the inflammation and pain; Cortavance, corticoid spray for inflammatory dermatosis in dogs; Curacef duo, an injectable suspension prescribed for treating respiratory diseases in cattle; Cyclavance, an oral solution prescribed for treating atopic dermatitis in dogs; Deltanil, a topical parasiticide for cattle and sheep; Donoban, a vaccine for swine; Easotic for otitis in dogs; Effipro to treat flea and tick infestations in dogs and cats; Effitix to treat tick, flea, and mosquito infestations in dogs; Epiotic, an ear cleanser used for dogs and cats; and Equimax, a horse wormer. Its products also include Floron to treat respiratory diseases in cattle; Flukazole C for the control of benzimidazole-sensitive worms in cattle and sheep; Gastrozol, an oral paste for horses; and Grofactor, a growth promoter for cattle; Indorex household flea sprays and foggers; and Iverhart for dogs. In addition, the company offers products under Mastinject, Milpro, Milteforan, Multimin, Neoprinil, Novifit, Ostovet, Penclox, Phenix, Preventic, Prodose, Pronefra, Rilexine, Shotapen, Soloxine, Speed Leish K, Suprelorin, Suramox, Tylaxen, Tylosin, Circovirus vaccine (PCV2), Vetflurane, Vet Complex, and Zoletil brands. Further, it provides contract manufacturing services. Virbac SA was founded in 1968 and is headquartered in Carros, France.

4,478 Employees
Last Reported Date: 04/23/15
Founded in 1968

virbac sa (VIRP) Top Compensated Officers

Chairman of the Executive Board, Chief Execut...
Total Annual Compensation: €529.6K
Chief Financial Officer, Member of the Execut...
Total Annual Compensation: €256.6K
Member of the Executive Board, Member of Stra...
Total Annual Compensation: €55.8K
Head of Global Business Operations and Member...
Total Annual Compensation: €312.5K
Chief Development Officer, Member of the Exec...
Total Annual Compensation: €341.5K
Compensation as of Fiscal Year 2014.

virbac sa (VIRP) Key Developments

Virbac SA Announces Revenue Results for the First Quarter of 2015

Virbac SA announced revenue results for the first quarter of 2015. For the quarter, the company reported net revenue of EUR 211.4 million, a 17.1% growth compared to the same period of 2014. This growth was driven by the acquisition of the Sentinel brands in the United States and favored by a positive evolution of the exchange rates.

Virbac Reports Audited Earnings Results for the Year Ended December 31, 2014

Virbac reported audited earnings results for the year ended December 31, 2014. For the year, the company reported current operating profit was EUR 109.0 million against EUR 104.9 million a year ago. Net consolidated profit was EUR 70.5 million against EUR 69.0 million a year ago. Net consolidated profit of which net profit group share was EUR 63.6 million against EUR 60.5 million a year ago. Net financial debt was EUR 196.6 million against EUR 178.1 million a year ago. Operating cash-flow before interest and tax was EUR 140.2 million against EUR 135.0 million a year ago. The slight increase of net debt in 2014 is due to payments made for recent acquisitions, essentially Centrovet in Chile, in relation to contractual price adjustments.

Virbac SA, 2014 Earnings Call, Mar 17, 2015

Virbac SA, 2014 Earnings Call, Mar 17, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VIRP:FP €232.10 EUR +1.00

VIRP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Phibro Animal Health Corp $33.67 USD +1.91
Sanofi €91.20 EUR -0.36
Valneva SE €3.91 EUR -0.05
Vetoquinol SA €35.40 EUR -0.08
Zoetis Inc $44.61 USD +0.19
View Industry Companies
 

Industry Analysis

VIRP

Industry Average

Valuation VIRP Industry Range
Price/Earnings 28.5x
Price/Sales 2.3x
Price/Book 4.2x
Price/Cash Flow 19.2x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VIRBAC SA, please visit www.virbac.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.